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Background and Purpose The pathophysiology of post-stroke depression (PSD) is complex and may 
differ according to an individual’s mood immediately after stroke. Here, we compared the 
therapeutic response and clinical characteristics of PSD at a later stage between patients with and 
without depression immediately after stroke. 
Methods This study involved a post hoc analysis of data from EMOTION (ClinicalTrials.gov 
NCT01278498), a placebo-controlled, double-blind trial that examined the efficacy of escitalopram 
(10 mg/day) on PSD and other emotional disturbances among 478 patients with acute stroke. 
Participants were classified into the Baseline-Blue (patients with baseline depression at the time of 
randomization, defined per the Montgomery-Asberg Depression Rating Scale [MADRS] ≥8) or the 
Baseline-Pink groups (patients without baseline depression). We compared the efficacy of 
escitalopram and predictors of 3-month PSD (MADRS ≥8) between these groups.
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Introduction 
Post-stroke depression (PSD) is common1,2 and negatively ef-
fects the course of stroke recovery in many patients.3 PSD has 
a dynamic natural course;4-8 while some patients develop de-
pression immediately following a stroke, others develop it later. 
This is partly because neurological deficits, which are strongly 
associated with PSD,9 change dynamically after stroke, espe-
cially in the acute/subacute stage.10
In the acute stage of stroke, depressive symptoms are fairly 
common. According to our recent EMOTION (the efficacy of 
escitalopram on post-stroke emotional disturbances and neu-
rologic dysfunction) trial,11 more than half of all acute stroke 
patients experience depression (per a Montgomery-Asberg De-
pression Rating Scale [MADRS] score ≥8)12 immediately follow-
ing the stroke. Although escitalopram was not effective in re-
ducing the prevalence of moderate to severe PSD (MADRS ≥16) 
at 3 months, it successfully decreased the rate of moderate 
PSD (MADRS 8–15) at 3 months. Notably, escitalopram was 
less effective at preventing PSD in the subacute stage in pa-
tients with baseline depressive symptoms (the Baseline-Blue 
group) than in those without (the Baseline-Pink group). These 
results suggest that the pathogenic mechanism(s) underlying 
depressive symptoms may differ between these groups. Con-
sidering the complex pathophysiology of PSD and the dynamic 
changes in associated factors such as neurological deficits, we 
hypothesized that patient response to antidepressants, risk fac-
tors, and clinical characteristics of PSD may differ by baseline 
depression status. In the present study, rather than severe PSD 
(MADRS ≥16), we employed a PSD defined by a MADRS ≥8 as 
the primary outcome of interest. This score had previously been 
found to be effectively reduced by escitalopram in a post hoc 
analysis of our data.11
Methods
Study design and participants
This is a post hoc analysis of the EMOTION trial.11 EMOTION 
was a 24-week, double-blind, placebo-controlled, multicenter 
trial, which assessed the efficacy of escitalopram on PSD and 
other emotional disturbances in patients who had experienced 
acute stroke. In this study, either escitalopram (10 mg/day) or 
placebo was randomly administered to the patients for 3 
months. The placebo was identical to escitalopram in color, 
shape, and size. Randomization was done in a 1:1 ratio using a 
web-based system with randomly permuted blocks of four to 
six and was stratified by center. Patients were followed until 6 
months post-stroke (3 months after discontinuation of the 
study medication). Detailed inclusion and exclusion criteria 
were described previously.11 Briefly, patients older than 20 with 
an acute stroke history (within 21 days of study onset) and a 
modified Rankin Scale score ≥2 were enrolled by investigators 
at each participating center. Patients who had a history of de-
pression prior to the index stroke were excluded. Intention-to-
treat analysis, which included all randomized participants, was 
used in this post hoc study. 
The EMOTION study (ClinicalTrials.gov NCT01278498) was 
conducted according to Good Clinical Practice guidelines and 
the Declaration of Helsinki and was approved by the Institu-
tional Review Boards of all participating centers. Informed 
consent was obtained from all participants. 
In this study, we categorized patients into two groups: the 
Baseline-Blue group, which included patients who experienced 
depression that developed immediately after the index stroke 
(MADRS ≥8) at the time of randomization, and the Baseline-
Pink group, which included those who did not.
Results There were 203 Baseline-Pink and 275 Baseline-Blue patients. The efficacy of escitalopram 
in reducing PSD risk was more pronounced in the Baseline-Pink than in the Baseline-Blue group (P 
for interaction=0.058). Several risk factors differentially affected PSD development based on the 
presence of baseline depression (P for interaction <0.10). Cognitive dysfunction was an independent 
predictor of PSD in the Baseline-Blue, but not in the Baseline-Pink group, whereas the non-use of 
escitalopram and being female were more strongly associated with PSD in the Baseline-Pink group. 
Conclusions Responses to escitalopram and predictors of PSD 3 months following stroke differed 
based on the presence of baseline depression. Our data suggest that PSD pathophysiology is 
heterogeneous; therefore, different therapeutic strategies may be needed to prevent PSD 
emergence following stroke. 
Keywords Depression; Stroke; Escitalopram; Anger; Emotional incontinence 
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Assessments
In the EMOTION study, patients’ depressive symptoms were eval-
uated with MADRS, which consists of a 10-item questionnaire 
(apparent sadness, reported sadness, inner tension, reduced 
sleep, reduced appetite, concentration difficulties, lassitude, in-
ability to feel, pessimistic thoughts, and suicidal thoughts) where 
each item yields a score from 0 to 6. A higher MADRS score indi-
cates more severe depression. PSD was defined as a MADRS 
score ≥8.12 Emotional incontinence was evaluated by Kim’s crite-
ria,2 anger proneness by the modified Spielberger trait anger 
scale (range from 0 to 40, a higher score indicates higher anger 
proneness),13 neurologic deficits by the National Institute of 
Health Stroke Scale (NIHSS),14 and cognitive function by the 
Montreal Cognitive Assessment (MoCA) (score range from 0 to 
30; a higher score denotes higher cognitive function).15 Changes 
in NIHSS scores during the initial month were calculated (“NI-
HSS score at baseline” – “NIHSS score at 1 month”) and used in 
the analysis of PSD risk factors. In the case of missing data (e.g., 
patients who dropped out before study termination), we used 
the most recently available records. 
Statistical analyses
For the univariate analysis, chi-square tests, Fisher’s exact tests, 
Student’s t-tests, or Mann-Whitney U tests were used. Baseline 
characteristics and clinical variables were compared between the 
Baseline-Pink group and the Baseline-Blue group. In addition, 
the efficacy of escitalopram 3 months post-stroke was analyzed 
within each group as were interactions between the effect of 
escitalopram and the presence of baseline depression. Next, pre-
dictors of PSD at 3 months were identified using a multivariable 
logistic regression model. First, we devised a model including all 
patients and then compared the odds ratio for each risk factor 
between the Baseline-Pink and Baseline-Blue groups, also con-
sidering interactions with the presence of baseline depression. To 
explore independent risk factors for PSD at 3 months, we con-
ducted univariate analyses and selected, for a final multivariable 
model, variables which: (1) were associated with baseline de-
pression, (2) were associated with PSD at 3 months. or (3) dem-
onstrated an interaction with baseline depression for the devel-
opment of PSD at 3 months. Variables with P-values <0.10 in 
any of these analyses were included in multiple logistic regres-
sion models. In a multivariable model for the full study cohort, 
the presence of baseline depression (MADRS ≥8) was also in-
cluded in the analysis to adjust for its effect. 
In addition, to examine whether characteristics of PSD are 
different according to baseline depression, emotional and neu-
rologic disturbances were compared between patients with 
PSD in the Baseline-Pink and the Baseline-Blue groups. A two-
tailed t-test value of P<0.05 was considered statistically sig-
nificant. For interactions, 0.05≤P<0.10 was regarded as a sig-
nificant trend.16 All statistical analyses were performed using 
SPSS version 22.0 (IBM Corp., Armonk, NY, USA) and SAS ver-
sion 9.4 (SAS Institute Inc., Cary, NC, USA). 
488 Patients in the EMOTION cohort
203 Included in analysis 275 Included in analysis
185 Completed evaluation at 3 months 243 Completed evaluation at 3 months
18 Lost to follow-up
   11 Withdrew consent
     4 Violated protocol
     3 Could not be reached
10 Had no baseline evaluation
     8 Withdrew consent
     2 Met exclusion criteria
32 Lost to follow-up
     2 Died
   15 Withdrew consent
   11 Violated protocol
     3 Were considered to be treated for depression
     1 Could not be reached
203 Not depressive at baseline 275 Depressive at baseline
478 Had baseline evaluation
Baseline
3 months
Figure 1. Trial profile. EMOTION, the efficacy of escitalopram on post-stroke emotional disturbances and neurologic dysfunction. 
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Results
Between January 27, 2011 and June 30, 2014, a total of 488 
patients were considered for their eligibility, 10 of whom were 
not included (Figure 1). Given this, 478 patients were included 
in the present intention-to-treat population and these analy-
ses. Their mean age was 64.0±12.1 years, and 187 (39.1%) 
were women. The median (interquartile range [IQR]) duration 
from stroke onset to study randomization was 7 days (IQR, 4 to 
10). At baseline, 275 patients (57.5%) had depression as de-
fined per the MADRS ≥8 (Baseline-Blue), while 203 did not 
(Baseline-Pink). Compared with the Baseline-Pink, the Base-
line-Blue patients were older, more often females, less often 
smokers, and more likely to have experienced emotional incon-
tinence, severe stroke, and cognitive dysfunction (Table 1). 
In the Baseline-Pink and Baseline-Blue patients, clinical vari-
ables at baseline were well-balanced between the escitalopram 
and placebo users except for a higher prevalence of emotional 
incontinence in the placebo arm of the Baseline-Pink group 
(Supplementary Table 1). Patient responses to escitalopram at 
3 months after initiation of therapy were stratified by group 
(Table 2). In the Baseline-Pink group, patients who were ran-
domized to escitalopram showed significantly lower MADRS 
scores and less frequent PSD (MADRS ≥8) at 3 months. In addi-
tion, NIHSS and anger scores tended to be lower among esci-
talopram users. In the Baseline-Blue group, although the esci-
talopram group was less likely to have PSD (MADRS ≥8) with a 
marginal statistical significance, escitalopram generally did not 
Table 1. Baseline characteristics of patients with initial depressive symptoms (Baseline-Blue) and those without (Baseline-Pink) 
Characteristic All patients (n=478) Baseline-Pink (n=203) Baseline-Blue (n=275) P *
Demographic and risk factors
Age (yr) 64.0±12.1 62.4±12.1 65.2±12.0 0.013 
Female sex 187 (39.1) 63 (31.0) 124 (45.1) 0.002 
Hypertension 360 (75.3) 156 (76.8) 204 (74.2) 0.504 
Diabetes 204 (42.7) 78 (38.4) 126 (45.8) 0.106 
Hyperlipidemia 235 (49.2) 98 (48.3) 137 (49.8) 0.739 
Coronary artery disease 63 (13.2) 24 (11.8) 39 (14.2) 0.451 
Smoking 230 (48.1) 112 (55.2) 118 (42.9) 0.008 
Time-to-randomization 7 (4—10) 7 (4—10) 7 (5—11) 0.206 
Lesion side 0.357 
Right 239 (50.0) 95 (46.8) 144 (52.4)
Left 208 (43.5) 96 (47.3) 112 (40.7)
Both 31 (6.5) 12 (5.9) 19 (6.9)
Lesion location
Anterior cortex 126 (26.4) 46 (22.7) 80 (29.1) 0.115 
Thalamus 43 (9.0) 21 (10.3) 22 (8.0) 0.376 
Medulla 39 (8.2) 16 (7.9) 23 (8.4) 0.849 
Cerebellum 37 (7.7) 13 (6.4) 24 (8.7) 0.347 
Posterior cortex 24 (5.0) 7 (3.4) 17 (6.2) 0.176 
Subcortex 226 (47.3) 96 (47.3) 130 (47.3) 0.997 
Pons+midbrain 106 (22.2) 44 (21.7) 62 (22.5) 0.821 
Clinical variables
MADRS 10.7±8.2 3.4±2.4 16.0±6.7 <0.001
NIHSS 4.8±2.9 4.2±2.3 5.3±3.1 <0.001
Emotional incontinence 32 (6.7) 6 (3.0) 26 (9.5) 0.005 
Anger proneness 22.8±5.7 22.6±5.4 22.9±5.9 0.528 
MoCA 18.4±6.9 19.8±6.5 17.4±7.1 <0.001
Values are presented as mean±standard deviation, number (%), or median (interquartile range). 
MADRS, Montgomery-Asberg Depression Rating Scale; NIHSS, National Institute of Health Stroke Scale; MoCA, Montreal Cognitive Assessment. 
*P via two-tailed t-test for Baseline-Pink vs. Baseline-Blue groups.
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improve emotional and neurological disturbances to a signifi-
cant degree. The favorable effect of escitalopram on patients’ 
depressive symptoms in the Baseline-Pink group was persistent 
up to 6 months after the index stroke (i.e., 3 months after 
medication cessation). Of note, there was a trend interaction 
between baseline depression and the effect of escitalopram on 
PSD prevention at 3 months (P for interaction=0.058), which 
was significant at 6 months (P for interaction=0.048). 
Next, we analyzed independent predictors of 3-month PSD 
and explored whether they would be different based on the 
presence of baseline depression. Candidate variables were se-
lected as those with a P<0.10. Differences between the Base-
line-Pink and the Baseline-Blue groups were significant in 
terms of age, female percentage, smoking rates, NIHSS, emo-
tional incontinence rates, and MoCA scores (Table 1). PSD at 3 
months was associated with old age, being female, a diagnosis 
of diabetes or hyperlipidemia, non-use of escitalopram, baseline 
NIHSS, anger levels, and MoCA scores (Table 3). The variables 
showing an interaction with baseline depression for 3-month 
PSD were non-use of escitalopram, anger scores, MoCA scores, 
and changes in NIHSS score (0 to 1 month) (Supplementary Ta-
ble 2). The presence of baseline depression (MADRS ≥8) was 
also adjusted via a multivariable model for all patients. 
In the final model (Table 4) including all patients, the pres-
ence of baseline depression (MADRS ≥8) was most strongly as-
sociated with PSD at 3 months. In addition, higher baseline NI-
HSS scores and anger scores, cognitive dysfunction, and non-
use of escitalopram were identified as independent predictors 
of the development of PSD at 3 months. Changes in NIHSS 
scores were marginally significant. We then assessed whether 
the effect of each risk factor on PSD at 3 months would differ 
according to the presence of baseline depression. In the Base-
line-Pink group, female sex, baseline NIHSS score, and non-use 
of escitalopram significantly increased the odds of PSD at 3 
months, while in the Baseline-Blue group, hyperlipidemia, 
higher anger scores, cognitive dysfunction (MoCA scores), 
changes in NIHSS scores, and non-use of escitalopram were 
significantly associated with PSD at 3 months. Among these 
variables, cognitive dysfunction, being female, and non-use of 
escitalopram demonstrated statistically significant interactions 
or trends towards interactions with baseline depression (P for 
interaction <0.10). Although non-use of escitalopram was an 
independent predictor of 3-month PSD in both the Baseline-
Pink and Baseline-Blue groups, the PSD odds ratio was sub-
stantially greater in the Baseline-Pink group than in the Base-
line-Blue group. 
Figure 2 illustrates changes in MADRS scores throughout the 
study period. In the Baseline-Pink group, placebo and escitalo-
pram users displayed different patterns; patients randomized 
to the placebo treatment showed a gradual increase in MADRS 
Table 2. Efficacy of escitalopram according to baseline depressive symptoms
Variable
Baseline-Pink Baseline-Blue
P for  
interaction*Placebo
(n=109)
Escitalopram
(n=94)
P Placebo
(n=128)
Escitalopram
(n=147)
P
At 3 months
PSD (MADRS score ≥8) 20 (18.3) 4 (4.3) 0.002 81 (63.3) 77 (52.4) 0.068 0.058
MADRS score 4.1±4.8 2.4±2.8 0.002 11.1±8.2 9.6±7.5 0.121 0.840
Emotional incontinence 10 (9.2) 5 (5.3) 0.295 15 (11.7) 10 (6.8) 0.157 0.987
NIHSS score 2.5±2.4 1.9±1.8 0.062 3.2±2.8 3.4±3.3 0.579 0.134
Anger score 21.1±4.9 19.7±5.1 0.059 21.8±5.8 21.1±5.6 0.300 0.543
MoCA score 21.9±6.6 22.1±6.9 0.806 20.0±6.8 18.8±7.5 0.155 0.258
At 6 months
PSD (MADRS score ≥8) 25 (22.9) 6 (6.4) 0.001 86 (67.2) 62 (42.2) 0.110 0.048
MADRS score 4.7±5.4 2.8±4.0 0.005 11.4±8.0 10.4±7.5 0.293 0.474
Emotional incontinence 11 (10.1) 9 (9.6) 0.902 16 (12.5) 12 (8.2) 0.236 0.503
NIHSS score 2.2±2.4 1.7±1.8 0.071 3.0±3.0 3.2±3.4 0.641 0.165
Anger score 20.7±5.2 20.0±5.5 0.379 21.4±5.8 21.3±6.1 0.928 0.573
MoCA score 22.2±6.8 22.2±7.1 0.969 20.0±7.1 19.1±7.6 0.278 0.451
Values are presented as number (%) or mean±standard deviation. 
PSD, post-stroke depression; MADRS, Montgomery-Asberg Depression Rating Scale; NIHSS, National Institute of Health Stroke Scale; MoCA, Montreal Cogni-
tive Assessment.
*P for interaction according to the presence of baseline depressive symptoms (MADRS ≥8).
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scores over time while those randomized to escitalopram dem-
onstrated an improvement; a significant difference in MADRS 
scores between treatment groups was demonstrated at 3 
months and maintained at 6 months. In the Baseline-Blue 
group, however, both placebo and escitalopram users showed a 
uniform decrease in MADRS scores for the first 3 months with-
out significant difference between treatment groups. Improve-
ments were most prominent during the first month and gradu-
ally diminished thereafter. 
Lastly, clinical characteristics were compared between PSD 
(at 3 months) patients in the Baseline-Pink and Baseline-Blue 
groups (Table 5). At baseline, all clinical variables, except for 
depressive symptoms and cognitive dysfunction, were compa-
rable. At 3 months, depressive symptoms (MADRS score) and 
cognitive dysfunction (MoCA score) remained diminished while 
emotional incontinence was more prevalent in PSD patients in 
the Baseline-Pink group. 
Discussion
We examined various clinical characteristics and factors asso-
ciated with PSD according to the depression levels immediately 
following a stroke. As the data were obtained as part of a ran-
domized controlled study, risk factors and clinical variables 
were prospectively collected and well balanced between the 
two treatment arms. We found that responses to escitalopram 
Table 3. Risk factors for post-stroke depression (MADRS ≥8) at 3 months in all the patients
Variable
PSD at 3 months
P
Without (n=296) With (n=182)
Demographic and risk factors
Age (yr) 62.5±11.8 66.4±12.4 0.001 
Female sex 107 (36.1) 80 (44.0) 0.089 
Hypertension 75 (25.3) 43 (23.6) 0.673 
Diabetes 116 (39.2) 88 (48.4) 0.049 
Hyperlipidemia 136 (45.9) 99 (54.4) 0.073 
Coronary artery disease 38 (12.8) 25 (13.7) 0.778 
Smoking 145 (49.0) 85 (46.7) 0.628 
Lesion side 0.131 
Right 144 (48.6) 95 (52.2)
Left 137 (46.3) 71 (39.0)
Both 15 (5.1) 16 (8.8)
Lesion location
Anterior cortex 72 (24.3) 54 (29.7) 0.198 
Thalamus 29 (9.8) 14 (7.7) 0.435 
Medulla 25 (8.4) 14 (7.7) 0.770 
Cerebellum 20 (6.8) 17 (9.3) 0.305 
Posterior cortex 13 (4.4) 11 (6.0) 0.422 
Subcortex 135 (45.6) 91 (50.0) 0.350 
Pons+Midbrain 61 (20.6) 45 (24.7) 0.293 
Clinical variables at baseline
Non-use of escitalopram (10 mg/day) 160 (54.1) 81 (44.5) 0.043 
MADRS 7.1±5.9 16.4±8.2 < 0.001
NIHSS score 4.4±2.6 5.5±3.1 < 0.001
Changes in NIHSS (0–1 mo) 1.5±1.6 1.3±1.5 0.147 
Emotional incontinence 21 (7.1) 11 (6.0) 0.655 
Anger score 22.1±5.8 23.9±5.2 < 0.001
MoCA score 19.7±6.3 16.3±7.3 < 0.001
Values are presented as mean±standard deviation or number (%). 
MADRS, Montgomery-Asberg Depression Rating Scale; PSD, post-stroke depression; NIHSS, National Institute of Health Stroke Scale; MoCA, Montreal Cogni-
tive Assessment.
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and predictors for PSD at 3 months differed between the Base-
line-Blue and Baseline-Pink groups. 
The efficacy of escitalopram was more marked in the Baseline-
Pink than in the Baseline-Blue group (Table 2). PSD risk and 
MADRS scores at 3 months were significantly lower in the esci-
talopram users than in the placebo users only in the Baseline-
Pink group. Of note, in reducing the PSD at 3 months, there was 
a trend interaction between baseline depression and escitalo-
pram use. Moreover, non-use of escitalopram was a more impor-
tant predictor of PSD at 3 months in the Baseline-Pink than in 
the Baseline-Blue groups (Table 4). Perhaps, in the Baseline-Blue 
group, factors such as neurologic recovery from severe deficits 
and a relatively low medication dose might have contributed to 
the relatively diminished effectiveness of escitalopram. Given 
higher baseline MADRS scores (mean of 16) in the Baseline-Blue 
group, a higher dose of escitalopram (>10 mg/day) might have 
been necessary to reduce PSD risk at 3 months.
Consistent with a previous report,17 baseline neurological dis-
ability, as assessed by the NIHSS, was a significant predictor of 
PSD in all participants in our study. However, the degree of neu-
rologic improvement (changes in NIHSS scores) during the first 
month was not an important determinant of PSD levels at 3 
months, although there was a trend relationship between neuro-
logic improvement and the decreased risk of PSD (odds ratio of 
0.88 according to one-point improvement of NIHSS score). In a 
previous report from our group, we reported that changes in NI-
HSS scores during an initial 3 months of treatment were closely 
associated with changes in MADRS scores in patients with base-
line depression (baseline MADRS ≥16 [r=0.206, P=0.040] or a 
baseline MADRS score of 8 to 15 [r=0.171, P=0.049]), but not in 
those without baseline depression (baseline MADRS <8 [r= 
–0.023, P=0.76]).11 Based on these findings, we speculated that 
patients with severe baseline depression and severe neurological 
deficits largely reflect a form of “reactive depression” that im-
proves over time along with neurological recovery, masking the 
efficacy of escitalopram. In this post hoc analysis, however, 
changes in NIHSS were not clearly identified as an independent 
risk factor for PSD in patients with baseline depression. Different 
time periods employed in our current and earlier studies may 
have affected the diverging results. In this study, we used a 
shorter time period of 1 month after the index stroke (rather 
than 3 months) to evaluate the predictive effect of NIHSS score 
change on the development of PSD at 3 months.
Follow-up (wk)
M
ea
n 
of
 M
AD
RS
0
0
5
10
15
20
4 12 24
Baseline-Pink: placebo
Baseline-Pink: escitalopram
Baseline-Blue: placebo
Baseline-Blue: escitalopram
Figure 2. Changes in Montgomery-Asberg Depression Rating Scale 
(MADRS) scores during the study period. *P<0.001.
Table 4. Independent predictors of post-stroke depression (MADRS ≥8) at 3 months
Variable
All patients Baseline-Pink Baseline-Blue P for  
interaction*OR (95% CI) P OR (95% CI) P OR (95% CI) P
Non-use of escitalopram (10 mg/day) 2.28 (1.44—3.64) <0.001 6.69 (1.96—22.86) 0.002 1.93 (1.12—3.33) 0.018 0.070
Age (/10 yr) 1.01 (0.99—1.03) 0.494 1.26 (0.79—2.00) 0.333 1.04 (0.80—1.36) 0.769 0.488
Female sex 1.36 (0.70—2.62) 0.363 4.46 (1.04—19.16) 0.044 1.05 (0.48—2.27) 0.911 0.085
Diabetes 1.14 (0.72—1.80) 0.569 0.59 (0.22—1.64) 0.317 1.26 (0.73—2.17) 0.407 0.203
Hyperlipidemia 1.48 (0.94—2.33) 0.088 0.97 (0.37—2.54) 0.945 1.78 (1.04—3.05) 0.035 0.277
Smoking 1.70 (0.89—3.26) 0.108 2.56 (0.69—9.52) 0.161 1.39 (0.64—3.05) 0.407 0.436
Emotional incontinence 0.48 (0.21—1.11) 0.085 0.52 (0.05—5.50) 0.589 0.46 (0.18—1.15) 0.096 0.919
Baseline NIHSS score 1.10 (1.01—1.20) 0.025 1.24 (1.01—1.54) 0.042 1.07 (0.97—1.17) 0.201 0.190
Anger score 1.06 (1.01—1.10) 0.010 1.01 (0.92—1.11) 0.815 1.08 (1.02—1.13) 0.004 0.268
MoCA score 0.95 (0.92—0.99) 0.021 1.07 (0.98—1.18) 0.125 0.92 (0.88—0.97) 0.001 0.005
Changes in NIHSS 0.88 (0.75—1.03) 0.104 1.04 (0.74—1.47) 0.816 0.83 (0.68—0.99) 0.046 0.248
Baseline depression (MADRS ≥8) 11.23 (6.58—19.17) <0.001 - -
MADRS, Montgomery-Asberg Depression Rating Scale; OR, odds ratio; CI, confidence interval; NIHSS, National Institute of Health Stroke Scale; MoCA, Mon-
treal Cognitive Assessment.
*P for interaction according to the presence of baseline depressive symptoms (MADRS ≥8).
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We found that baseline cognitive dysfunction, measured by 
MoCA, was associated with PSD at 3 months across all patients 
(Table 4). Cognitive dysfunction, as measured by tools such as 
Mini-Mental State examination18 and Abbreviated Memory 
Test,19 has been shown to be associated with PSD.8 However, 
we also found that baseline cognitive dysfunction, which was 
more common in the Baseline-Blue group, was a significant 
predictor for PSD only among Baseline-Blue patients and not 
among Baseline-Pink patients (Table 4). In addition, among pa-
tients with PSD at 3 months, cognitive function was worse in 
the Baseline-Blue group than in the Baseline-Pink group (Table 
5). The association between cognitive decline and persistent 
depression may, in part, be related to shared diagnostic items 
such as “difficulty in concentration.” Alternatively, both depres-
sion and cognitive dysfunction may be common manifestations 
of damage in certain structures such as the frontal lobes or 
multiple small vessels which cause white matter changes. Un-
fortunately, this study was not able to explore the impact of 
small vessel disease on depression and cognitive dysfunction.
Generally, females are known to have a higher risk of PSD 
than males.20 Less social support after the index stroke may re-
sult in this outcome, considering that female patients are re-
ported to receive relatively little support from both health care 
providers and the broader community.21,22 In our study, being 
female was not an independent predictor of PSD in all of the 
patients. However, being female increased the risk of PSD in 
the Baseline-Pink group but not in the Baseline-Blue group. 
The reason for this remains elusive. We speculate that, in the 
Baseline-Blue group there were other strong predictors (e.g., 
more severe neurologic deficits and cognitive dysfunction) of 
PSD and thus the contribution of sex to PSD might have been 
masked by our use of a multiple variable model. 
Our results suggest that different approaches are necessary 
to treat/prevent PSD based on the presence of baseline depres-
sion. In patients without baseline depression, depressive symp-
toms gradually worsened over time if a placebo was given but 
Table 5. Group-based differences in the clinical characteristics of patients with post-stroke depressive symptoms 3 months following stroke 
Characteristic
PSD at 3 months
P
Baseline-Pink (n=24) Baseline-Blue (n=158)
Demographics
Age (yr) 62 (51—78) 69 (59—76) 0.344 
Female sex 10 (41.7) 70 (44.3) 0.808 
Lesion location
Anterior cortex 6 (25.0) 48 (30.4) 0.591 
Thalamus 1 (4.2) 13 (8.2) 0.698 
Medulla 1 (4.2) 13 (8.2) 0.698 
Cerebellum 1 (4.2) 16 (10.1) 0.704 
Posterior cortex 1 (4.2) 10 (6.3) >0.999
Subcortex 14 (58.3) 77 (48.7) 0.381 
Pons+Midbrain 6 (25.0) 39 (24.7) >0.999
Clinical variables at baseline
MADRS 4 (2—6) 18 (12—24) <0.001
NIHSS score 4 (3—7) 5 (3—7) 0.831 
Emotional incontinence 1 (4.2) 10 (6.3) >0.999
Anger score 24 (19—26) 24 (21—28) 0.280 
MoCA score 23 (15—27) 16 (11—21) 0.002 
Clinical variables at 3 months
MADRS 11 (9—14) 14 (11—20) 0.004 
NIHSS score 3 (1—5) 3 (1—6) 0.265 
Emotional incontinence 6 (25.0) 14 (8.9) 0.030 
Anger score 23 (18—26) 23 (20—26) 0.517 
MoCA score 27 (18—28) 19 (11—23) <0.001
Values are presented as median (interquartile range) or number (%).
PSD, post-stroke depression; MADRS, Montgomery-Asberg Depression Rating Scale; NIHSS, National Institute of Health Stroke Scale; MoCA, Montreal Cogni-
tive Assessment. 
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improved with escitalopram (Figure 2). Escitalopram appears to 
be effective in this group of patients (Table 4) and therefore 
active pharmacological prevention might be a reasonable ap-
proach, especially in female patients or those with a mild 
stroke. Our findings align with a recent meta-analysis that re-
ported on the efficacy of selective serotonin reuptake inhibitors 
(SSRIs) in preventing depression among initially non-depressed 
stroke patients.23 However, given a low rate of PSD develop-
ment at 3 months (approximately 18%) in the placebo users of 
the Baseline-Pink group, the cost-effectiveness and feasibility 
of this approach needs to be further evaluated. In contrast, in 
the Baseline-Blue group, escitalopram was found to be less ef-
fective and PSD was more closely related to neurological im-
provements. Given this, early and active rehabilitation may be 
necessary to promote the improvement of neurologic deficits 
and consequently of depressive symptoms in this group of pa-
tients. However, it should be further noted that, we used fixed 
doses (10 mg) of escitalopram for a set duration (3 months). 
Therefore, it remains to be studied whether a higher dose and/
or longer duration of escitalopram administration,24 or the use 
of another class of antidepressant, would be more effective in 
treating Baseline-Blue patients.
Finally, among patients with PSD at 3 months, patients with-
out baseline depression were more likely to have newly-devel-
oped emotional incontinence as compared to those with base-
line depression (Table 5). It has been reported that emotional 
incontinence was closely associated with damages to subcorti-
cal structures (e.g., the basal ganglia or internal capsule).2,25 
Because there are abundant serotonergic fibers in these ar-
eas,26 altered neurotransmission after ischemic brain damage 
may play a role in the development of emotional incontinence.9 
The more frequent development of emotional incontinence and 
relatively good response rates to escitalopram suggest that de-
pressive symptoms in the Baseline-Pink group may be more 
closely associated with neurochemical changes27 due to brain 
damage than those in the Baseline-Blue group.
There are a number of limitations in the present study. First, 
we utilized post hoc analyses data from a randomized con-
trolled trial. Therefore, baseline variables could not be balanced 
with the efficacy of escitalopram in each study group. Second, 
all patients were ethnically Korean, and the generalizability of 
our results to other ethnic populations may be limited. Third, in 
this clinical trial, we did not compile information on items such 
as patient socioeconomics, job status, or familial/social sup-
port, which may play roles in the development of depression.27 
Finally, we examined the efficacy of escitalopram with a fixed 
dosage (10 mg/day) for a limited period.
Despite these limitations, our results demonstrate that pa-
tient responses to escitalopram and predictors of PSD at 3 
months may vary according to the presence of depression im-
mediately following stroke. These findings highlight the het-
erogeneity of PSD pathophysiology and suggest the require-
ment for tailored therapeutic approaches in stroke patients 
who are at risk of PSD.
Supplementary materials
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Supplementary Table 1. Baseline characteristics of patients (placebo vs. escitalopram)
Characteristic
Baseline-Pink Baseline-Blue
Placebo (n=109) Escitalopram (n=94) P Placebo (n=128) Escitalopram (n=147) P
At baseline
Age (yr) 63.0±12.5 61.7±11.8 0.452 64.9±11.3 65.4±12.7 0.746 
Female sex 32 (29.4) 31 (33.0) 0.578 54 (42.2) 70 (47.6) 0.367 
Hypertension 80 (73.4) 76 (80.9) 0.209 97 (75.8) 107 (72.8) 0.572 
Diabetes 47 (43.1) 31 (33.0) 0.139 55 (43.0) 71 (48.3) 0.376 
Hyperlipidemia 57 (52.3) 41 (43.6) 0.217 62 (48.4) 75 (51.0) 0.669 
Coronary artery disease 12 (11.0) 12 (12.8) 0.699 18 (14.1) 21 (14.3) 0.958 
Smoking 59 (54.1) 53 (56.4) 0.747 51 (39.8) 67 (45.6) 0.338 
Lesion side 0.097 0.739 
Right 55 (50.5) 40 (42.6) 70 (54.7) 74 (50.3)
Left 45 (41.3) 51 (54.3) 49 (38.3) 63 (42.9)
Both 9 (8.3) 3 (3.2) 9 (7.0) 10 (6.8)
Clinical variables
MADRS 3.6±2.3 3.2±2.5 0.320 16.6±6.7 15.5±6.7 0.222 
NIHSS 4.2±2.6 4.2±2.1 0.922 5.2±3.0 5.3±3.2 0.686 
Emotional incontinence 6 (5.5) 0 0.021 12 (9.4) 14 (9.5) 0.966 
Anger proneness 22.9±5.1 22.1±5.7 0.278 23.2±5.6 22.6±6.1 0.405 
MoCA 20.0±6.4 19.6±6.6 0.656 18.1±6.9 16.8±7.2 0.145 
Values are presented as mean±standard deviation or number (%). 
MADRS, Montgomery-Asberg Depression Rating Scale; NIHSS, National Institute of Health Stroke Scale; MoCA, Montreal Cognitive Assessment.
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Supplementary Table 2. Risk factors of post-stroke depressive symptoms at 3 months by the presence of baseline depression
Variable
Crude odds ratio (95% CI) P for interaction with 
baseline depressionBaseline-Pink (n=296) Baseline-Blue (n=182)
Demographic and risk factors
Age (/10 yr) 1.01 (0.97—1.05) 1.03 (1.01—1.05)* 0.372 
Female sex 1.70 (0.71—4.06) 0.93 (0.57—1.50) 0.235 
Hypertension 0.89 (0.33—2.39) 1.34 (0.78—2.31) 0.479 
Diabetes 0.78 (0.32—1.92) 1.58 (0.98—2.57) 0.174 
Hyperlipidemia 1.08 (0.46—2.54) 1.64 (1.01—2.66)† 0.403 
Coronary artery disease 0.30 (0.04—2.29) 1.22 (0.61—2.44) 0.199 
Smoking 1.16 (0.49—2.74) 1.22 (0.75—1.97) 0.923 
Lesion side 0.879 
Left vs. Right 0.99 (0.41—2.40) 0.82 (0.50—1.36)
Both vs. Right 1.53 (0.30—7.90) 2.00 (0.68—5.85)
Lesion location
Anterior cortex 1.16 (0.43—3.11) 1.16 (0.68—1.97) 0.999 
Thalamus 0.35 (0.04—2.70) 1.08 (0.44—2.61) 0.320 
Medulla 0.48 (0.06—3.77) 0.96 (0.41—2.27) 0.540 
Cerebellum 0.61 (0.08—4.87) 1.54 (0.63—3.72) 0.421 
Posterior cortex 1.25 (0.14—10.88) 1.06 (0.39—2.88) 0.891 
Subcortex 1.66 (0.70—3.93) 1.15 (0.71—1.85) 0.467 
Pons+Midbrain 1.24 (0.46—3.33) 1.34 (0.75—2.40) 0.892 
Clinical variables at baseline
Non-use of escitalopram (10 mg/day) 5.00 (1.67—14.29)* 1.56 (0.96—2.56) 0.058 
MADRS 1.19 (0.98—1.44) 1.16 (1.11—1.22)* 0.791 
NIHSS score 1.25 (1.05—1.48)† 1.07 (0.99—1.16) 0.117 
Changes in NIHSS (0–4 wk) 1.12 (0.86—1.46) 0.86 (0.73—1.00)† 0.082 
Emotional incontinence 1.51 (0.17—13.53) 0.43 (0.19—0.98)† 0.289 
Anger score 1.00 (0.92—1.08) 1.09 (1.04—1.14)* 0.053 
MoCA score 1.02 (0.95—1.09) 0.92 (0.88—0.95)* 0.008 
CI, confidence interval; MADRS, Montgomery-Asberg Depression Rating Scale; NIHSS, National Institute of Health Stroke Scale; MoCA, Montreal Cognitive 
Assessment.
*P<0.01; †P<0.05.
